KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir's oncolytic immunotherapy VETTM platform.
KaliVir will work with Roche to leverage KaliVir's proprietary technology platform based on genetically modified vaccinia virus to discover and develop novel oncolytic virus candidates. KaliVir's VETTM platform can enhance the vaccinia viral backbone with a combination of proprietary genetic modifications to maximize tumor killing and systemic delivery and spread, and can be readily optimized to combine with a wide variety of therapeutic transgenes.
Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company's VETTM platform expressing Roche proprietary therapeutic transgenes. Roche will have exclusive license to discover, develop and commercialize the products worldwide. KaliVir will receive an upfront payment, and may be eligible to receive research, development and commercial milestone payments, as well as tiered royalties on commercial sales of products emerging from the collaboration.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.